SCHEMBL3784871

SCHEMBL3784871

CCOC(=O)C(Cc1ccc(F)cc1)C(=O)CC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.49
EPHX2 P34913 1/20 0.49
MMP8 P22894 1/20 0.49
GAA P10253 2/20 0.43
MAPK1 P28482 1/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 2/20 0.43
LMNA P02545 2/20 0.43
KMT2A Q03164 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 1/20 0.43
ALOX12 P18054 1/20 0.43
CCR6 P51684 1/20 0.43
HKDC1 Q2TB90 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7436472 0.90 MMP8 (0.54) PPARGEPHX2MMP8GAAMAPK1
SCHEMBL3779421 0.88 NOS2 (0.48) PPARGEPHX2GAAMAPK1MEN1
SCHEMBL3989322 0.87 MMP8 (0.55) PPARGEPHX2MMP8MAPTMEN1
SCHEMBL2429506 0.86 PPARG (0.50) PPARGEPHX2MMP8GAAMAPK1
SCHEMBL534123 0.84 MMP8 (0.52) MMP8MAPK1MAPTMEN1LMNA
SCHEMBL534033 0.84 EPHX2 (0.49) PPARGEPHX2MMP8MAPTMEN1
SCHEMBL15261624 0.84 MMP8 (0.42) PPARGEPHX2MMP8MAPK1MEN1
SCHEMBL15647978 0.84 PPARG (0.53) PPARGEPHX2MMP8MAPTMEN1
SCHEMBL534859 0.83 ALDH1A1 (0.48) PPARGEPHX2MMP8LMNAKMT2A
SCHEMBL2570738 0.83 LDHA (0.61) PPARGEPHX2MMP8MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 PPARG 522/4885EPHX2 1169/4885MMP8 992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.